blood–brain barrier

Overview

The blood–brain barrier (BBB) is a specialized biological interface formed primarily by brain microvascular endothelial cells and their associated supporting cells, including astrocytes and pericytes. It tightly regulates the exchange of molecules, ions, and cells between the bloodstream and the central nervous system (CNS), thereby maintaining neural homeostasis and protecting the brain from toxins, pathogens, and inflammatory mediators. Functionally, the BBB is not a passive wall but a dynamic, selectively permeable barrier whose properties can change in development, adulthood, aging, and disease.

From a biomedical perspective, the BBB is central to both neuroprotection and therapeutic delivery. Its restrictive transport properties limit entry of many drugs, including agents intended for Alzheimer’s disease, glioblastoma, epilepsy, fungal encephalitis, and other CNS disorders. At the same time, BBB disruption is a hallmark of several pathological states, including ischemic stroke, meningitis, neuroinflammation, and brain metastasis, where barrier breakdown can worsen injury or alter disease progression. Transport systems such as LAT1 and P-glycoprotein (P-gp) are frequently studied because they influence BBB penetration and oral bioavailability of candidate therapeutics.

Recent Publications Summary

Recent studies have examined the blood–brain barrier (BBB) as both a therapeutic target and a biomarker of injury across neurological and oncologic settings. In traumatic brain injury (TBI), lyophilized platelet-derived extracellular vesicles and a dried platelet-derived biologic were investigated for their ability to preserve BBB integrity, reduce intracranial hemorrhage, and improve vascular stability after injury. In murine TBI models, these platelet-derived products reduced BBB permeability, attenuated hemorrhage, and were associated with reduced neuroinflammation; the dried platelet-derived biologic also restored cerebral vascular perfusion and was enriched in angiopoietin-1, suggesting a mechanism linked to vascular repair 42472813Jul41843452Mar.

BBB disruption was also evaluated in ischemic stroke, where pre-transfer BBB status before interhospital transfer for thrombectomy was studied as a predictor of hemorrhagic transformation and 3-month functional outcome 42385121Jul. In a separate ischemic stroke study, NADPH was reported to reinforce BBB integrity, reduce infarct volume and cerebral edema, and improve neurological function in a transient middle cerebral artery occlusion model. Mechanistically, this was associated with increased tight junction protein expression, including ZO-1, and reduced levels of matrix metalloproteinase-9 and caveolin-1, supporting a barrier-protective and angiogenesis-promoting role for NADPH 41638470Feb.

Several publications focused on BBB penetration as a key property for CNS-directed therapeutics. The tumor-targeting peptide p28 was described as crossing the BBB while enhancing chemotherapy, inducing apoptosis, and suppressing metastasis in triple-negative breast cancer models, including those relevant to CNS spread 42095973May. Similarly, biotin-decorated inulin-based polymeric micelles were designed to target both the BBB and glioblastoma multiforme cells, with in vitro and in vivo studies supporting their dual-targeting potential for curcumin delivery 41973041Apr.

BBB disruption was also linked to disease mechanisms in Alzheimer’s disease. In patients with Alzheimer’s disease and high body mass index, cerebrospinal fluid markers consistent with BBB disruption were elevated alongside neuroinflammatory markers, and these changes were associated with gut dysbiosis and worse cognition 42227185Jun. In another Alzheimer’s disease-focused study, an AI-enabled screening platform identified BBB-permeable autophagy enhancers; two lead compounds were reported to cross the BBB, clear Alzheimer’s disease-related protein aggregates, and restore memory function in worm and mouse models 42032039Apr.

What Changes, What Holds

1. Platelet-derived vesicles may preserve barrier integrity after traumatic injury
NEW DIRECTION These studies extend the BBB account into acute repair biology: rather than only being disrupted in injury, the barrier can be actively stabilized by platelet-derived biologics after TBI. That does not overturn the baseline, but it adds a therapeutic strategy aimed at preserving vascular integrity, limiting hemorrhage, and dampening neuroinflammation. The evidence is still preclinical, so the key unsettled question is whether the same barrier-protective effect translates to human traumatic brain injury and meaningful functional benefit 42472813Jul41843452Mar.

2. BBB status before stroke intervention may help stratify risk, and NADPH appears barrier-protective
NEW DIRECTION Pre-transfer BBB disruption becomes a prognostic variable in ischemic stroke care, adding a biomarker role to the barrier beyond its established function as a pathophysiologic feature of stroke. At the same time, NADPH is reported to strengthen barrier integrity and improve outcomes in experimental stroke, which fits the baseline’s view of BBB protection as beneficial but remains mechanistically and clinically unproven. Together, these findings suggest the BBB is both a target for therapy and a candidate marker for triage, but validation in patients is still needed 42385121Jul41638470Feb.

3. BBB penetration is being used more deliberately to design CNS-directed cancer delivery
REINFORCES These studies do not change what the BBB is; they sharpen the therapeutic problem the baseline already identifies, namely that CNS drug delivery is limited by barrier penetration. The new work shows that BBB-crossing can be engineered into anti-cancer platforms, including agents intended to reach brain-involved disease, but that is an application of the established delivery challenge rather than a new biological role. The main implication is practical: BBB permeability is increasingly treated as a design criterion for oncology therapeutics 42095973May41973041Apr.

4. BBB disruption is emerging as part of Alzheimer’s disease biology and a treatment target
NEW DIRECTION These findings add two roles not covered in the baseline: BBB disruption as a measurable disease-associated biomarker in Alzheimer’s disease, and BBB permeability as a property that can be exploited to deliver autophagy-enhancing therapies. That leaves the established account intact while broadening it from a barrier that limits CNS drug entry to one that may also report metabolic/inflammatory risk and be intentionally crossed for disease modification. The human association is correlative, so causality and clinical utility remain unsettled 42227185Jun42032039Apr.

Overview update candidates: BBB disruption as a biomarker in Alzheimer’s disease; pre-transfer BBB status as a prognostic marker in ischemic stroke; platelet-derived biologics as BBB-stabilizing therapies after traumatic brain injury.